News | September 27, 2024
Sun Pharma presents clinical efficacy and safety data in severe dermatological conditions at 2024 EADV Congress
The company will also share results in two additional posters for deuruxolitinib
The company will also share results in two additional posters for deuruxolitinib
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Pfizer's decision is based on the totality of clinical data
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
New Phase II data show vast majority of patients experiencing no relapses or disability progression
Subscribe To Our Newsletter & Stay Updated
